Tehran University of Medical Sciences

Science Communicator Platform

Share By
Nanomaterials As a Therapeutic Platform for Covid-19 Publisher



Nasab MHF ; Manavi MA ; Hamrahi M ; Khonsari F ; Gelivarisarshari M ; Foroohari A ; Dehghani M ; Ranjbar S ; Atyabi F
Authors

Source: Precision Nanomedicine Published:2026


Abstract

COVID-19 remains a major global health challenge, highlighting the urgent need for more effective treatments. Nanotechnology-based drug delivery systems provide a promising platform for overcoming the limitations of traditional antiviral, anti-inflammatory, and immunomodulatory therapies. Carefully designed nanocarriers can improve how drugs move through the body, reach target cells, and are taken up, increasing antiviral effectiveness and potentially lowering systemic toxicity. In addition to serving as carriers for approved antiviral drugs, many nanomaterials possess their own antiviral properties. Since dysregulated inflammation and cytokine storms are key factors in severe COVID-19, nanomedicine also offers ways to deliver anti-inflammatory and immunomodulatory agents directly to sites of immune activation, enabling more precise control of interleukin and cytokine release. This review covers recent developments in the design and use of nanocarriers and nanomaterials for the prevention, diagnosis, and treatment of COVID-19, and discusses future prospects for nanotechnology in the management of viral infections. ©The Author(s) 2024.
Other Related Docs
10. Therapeutic Potentials and Candidates for Covid-19, Iranian Journal of Science (2023)
18. Therapeutic Strategies for Covid-19 Patients: An Update, Infectious Disorders - Drug Targets (2022)